Tunicamycin potentiates cisplatin anticancer efficacy through the dpagt1/akt/abcg2 pathway in mouse xenograft models of human hepatocellular carcinoma

Molecular Cancer Therapeutics

Volumn 12, Issue 12, 2013, Pages 2874-2884

  Hou, Helei ^a   Sun, Hefen ^b   Lu, Ping ^c   Ge, Chao ^a   Zhang, Lixing ^a   Li, Hong ^a   Zhao, Fangyu ^a   Tian, Hua ^a   Zhang, Lin ^a   Chen, Taoyang ^d   Yao, Ming ^a   Li, Jinjun ^a  

^a School of Medicine   (United States)

^b Department of Breast Surgery   (United States)

^c FUDAN UNIVERSITY   (China)

^d Qi Dong Liver Cancer Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CISPLATIN; CYCLINE; DOXORUBICIN; PROTEIN KINASE B; TUNICAMYCIN; UDP GLCNAC DOLICHOL PHOSPHATE N ACETYLGLUCOSAMINE 1 PHOSPHATE TRANSFERASE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENICITY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GLYCOSYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN STABILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HUMANS; INTRACELLULAR SPACE; LIVER NEOPLASMS; MICE; N-ACETYLGLUCOSAMINYLTRANSFERASES; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUNICAMYCIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890492751     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0201     Document Type: Article

References (45)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
2. Vermeulen L, de Sousa EMF, Richel DJ, Medema JP. The developing cancer stem-cell model: Clinical challenges and opportunities. Lancet Oncol 2012;13:e83-9.
3. Maugeri-Sacca M, Vigneri P, De Maria R. Cancer stem cells and chemosensitivity. Clin Cancer Res 2011;17:4942-7.
4. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011; 9:50-63
5. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012;488:522-6.
6. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007;120:1444-50.
7. + population in hepatocellular carcinoma. Int J Cancer 2010;126:2067-78.
8. Zen Y, Fujii T, Yoshikawa S, Takamura H, Tani T, Ohta T, et al. Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am J Pathol 2007;170:1750-62.
9. Zhou S, Schuetz JD, Bunting KD, Colapietro AM,Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide varietyof stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7:1028-34.
10. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34.
11. Bhattacharya S, Das A, Mallya K, Ahmad I. Maintenance of retinal stem cells by ABCG2 is regulated by notch signaling. J Cell Sci 2007; 120:2652-62.
12. Nakanishi T, Shiozawa K, Hassel BA, Ross DD. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRPmediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 2006;108:678-84.
13. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 2011;53:160-70.
14. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.Cell Stem Cell 2009;4:226-35
15. HuC, Li H, Li J, Zhu Z, Yin S,Hao X, et al. Analysis ofABCG2expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 2008;29:2289-97.
16. Parodi AJ. Role of N-oligosaccharide endoplasmic reticulum processing reactions in glycoprotein folding and degradation. Biochem J 2000;348:1-13.
17. Nakagawa H, Wakabayashi-Nakao K, Tamura A, Toyoda Y, Koshiba S, Ishikawa T. Disruption of N-linked glycosylation enhances ubiquitinmediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2. FEBS J 2009;276:7237-52.
18. Banerjee A, Lang JY, Hung MC, Sengupta K, Banerjee SK, Baksi K, et al. Unfolded protein response is required in nu/nu mice microvasculature for treating breast tumor with tunicamycin. J Biol Chem 2011;286:29127-38.
19. De-Freitas-Junior JC, Bastos LG, Freire-Neto CA, Rocher BD, Abdelhay ES, Morgado-Diaz JA. N-glycan biosynthesis inhibitors induce in vitro anticancer activity in colorectal cancer cells. J Cell Biochem 2012;113:2957-66.
20. Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, et al. Tunicamycin enhances tumor necrosis factor-related apoptosisinducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res 2005;65:6364-70.
21. Hiss DC, Gabriels GA, Folb PI. Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrugresistant human ovarian cystadenocarcinoma cells. Cancer Cell Int 2007;7:5.
22. Goss PE, Baker MA, Carver JP, Dennis JW. Inhibitors of carbohydrate processing: A new class of anticancer agents. Clin Cancer Res 1995; 1:935-44.
23. Santos FM, Latorre AO, Hueza IM, Sanches DS, Lippi LL, Gardner DR, et al. Increased antitumor efficacy by the combined administration of swainsonine and cisplatin in vivo. Phytomedicine 2011; 18:1096-101.
24. Kurtoglu M, Gao N, Shang J, Maher JC, Lehrman MA, Wangpaichitr M, et al. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with Nlinked glycosylation. Mol Cancer Ther 2007;6:3049-58.
25. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004;64:31-4.
26. Li H, Ge C, Zhao F, Yan M, Hu C, Jia D, et al. Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin beta1 signaling in human hepatocellular carcinoma. Hepatology 2011;54:910-9.
27. Barik S. Site-directed mutagenesis in vitro by megaprimer PCR. Methods Mol Biol 1996;57:203-15.
28. Mohrmann K, van Eijndhoven MA, Schinkel AH, Schellens JH. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemother Pharmacol 2005;56:344-50.
29. Hanusova V, Bousova I, Skalova L. Possibilities to increase the effectiveness of doxorubicin in cancer cells killing. Drug Metab Rev 2011;43:540-57.
30. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008;27:1749-58.
31. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42.
32. Suetsugu A, Osawa Y, Nagaki M, Moriwaki H, Saji S, Bouvet M, et al. Simultaneous color-coded imaging to distinguish cancer "stem-like" and non-stem cells in the same tumor. J Cell Biochem 2010;111:1035-41
33. Ling YH, Li T, Perez-Soler R, Haigentz MJ. Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib. Cancer Chemother Pharmacol 2009;64:539-48.
34. Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, et al. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 2010;102:1637-52.
35. Wang H, Galban S,WuR, Bowman B, Witte A, Vetter K, et al. Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma. Clin Cancer Res 2013;19:158-69.
36. Niu Q, Wang W, Li Y, Ruden DM, Wang F, Li Y, et al. Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediatedABCG2protein degradation. PLoS One 2012;7: e41035
37. Song L, Ma L, Zhang X, Jiang Z, Liu H, Jiang C. Effect of tunicamycin combined with cisplatin on proliferation and apoptosis of human nasopharyngeal carcinoma cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2012;32:766-71.
38. Nita-Lazar M, Noonan V, Rebustini I, Walker J, Menko AS, Kukuruzinska MA. Overexpression of DPAGT1 leads to aberrant N-glycosylation of E-cadherin and cellular discohesion in oral cancer. Cancer Res 2009;69:5673-80.
39. Jamal B, Sengupta PK, Gao ZN, Nita-Lazar M, Amin B, Jalisi S, et al. Aberrant amplification of the crosstalk between canonical Wnt signaling and N-glycosylation gene DPAGT1 promotes oral cancer. Oral Oncol 2012;48:523-9.
40. Monga SP. Role of Wnt/beta-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol 2011;43:1021-9.
41. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/ PRF/5. Cancer Res 2006;66:11851-8.
42. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
43. Zhang W, Sun HC, Wang WQ, Zhang QB, Zhuang PY, Xiong YQ, et al. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. Gastroenterology 2012;143:1641-9.
44. Morin MJ, Bernacki RJ. Biochemical effects and therapeutic potential of tunicamycin in murine L1210 leukemia. Cancer Res 1983;43: 1669-74.
45. Contessa JN, Bhojani MS, Freeze HH, Rehemtulla A, Lawrence TS. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res 2008;68:3803-9.